The use of apixaban for stroke prevention in patients with atrial fibrillation (AF) and liver cirrhosis appears to be safer than other common anticoagulants, a new observational study shows. When ...
For patients with HIV and atrial fibrillation, this study found that apixaban was associated with less bleeding when compared with warfarin and rivaroxaban. Data remain inconclusive regarding ...
In patients with venous thromboembolism (VTE) who are candidates for oral anticoagulation, apixaban results in fewer hospitalizations for recurrence and less major bleeding than rivaroxaban or ...
The appropriate duration of anticoagulation for venous thromboembolism (VTE) in patients who have a transient provoking factor (e.g., surgery, trauma, or immobility) and concomitant enduring risk ...
Please provide your email address to receive an email when new articles are posted on . Asundexian did not prevent stroke or systemic embolism vs. apixaban in patients with atrial fibrillation despite ...
In patients with active cancer and venous thromboembolism, whether extended treatment with a reduced dose of an oral anticoagulant is effective in preventing recurrent thromboembolic events and ...
The Eliquis 360 Support program offers a 40% discount on apixaban, targeting uninsured or underinsured patients to improve access and affordability. Apixaban is the most prescribed oral anticoagulant ...
TAHO Pharmaceuticals Ltd. ("TAHO Pharma") today announced the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for TAH3311, the world's first Apixaban Oral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback